(
out of
25
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital North
2K, Gynecology and Mammography
1950 Circle of Hope
Salt Lake City
,
UT
84112
Specialties
Board Certification
|
American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)
|
Patient Rating
Patients consistently describe Dr. Apte as caring, respectful, and professional, with a comforting bedside manner. Reviewers highlight clear, patient explanations and attentive listening, noting that visits are not rushed and that they feel involved in decisions about their care. Many also praise his expertise and the supportive communication from his staff, which helps reduce anxiety during treatment.
Generated via Patient Reviews
5.0
/5
( out of
25 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Obstetrics & Gynecology
-Professor |
|---|---|
| Academic Divisions |
Gynecological Oncology
|
| Board Certification |
American Board of Obstetrics & Gynecology (Obstetrics & Gynecology)
American Board of Obstetrics & Gynecology (Sub: Gynecologic Oncology)
|
Education history
| Undergraduate | Chemical Engineering - Cornell University | B.S. |
|---|---|---|
| Professional Medical | Medicine - Ohio State University College of Medicine | M.D. |
| Internship/Residency | Obstetrics & Gynecology - Ohio State University College of Medicine | Intern/Resident |
| Graduate Training | Cancer Biology - University of Texas, Health Science Center at Houston | M.S. |
| Fellowship | Gynecologic Oncology - University of Texas M.D. Anderson Cancer Center | Fellow |
| Graduate Training | Business - University of Tennessee | M.B.A. |
Selected Publications
Journal Article
- Wenham RM, Buras AL, Gordon SW, Whiting J, Fridley BL, Dorman D, Apte SM, Chon HS, Shahzad MM, Randall LM, Havrilesky LJ, Davidson BA, Secord A (2025). A Phase 2 Study of Pembrolizumab and Weekly Paclitaxel for Platinum-Resistant Epithelial Ovarian Cancer. International Journal of Gynecological Cancer,
- Liang MI, Aviki EM, Wright JD, Havrilesky LJ, Boyd LR, Moss HA, Jewell EL, Cohn DE, Apte SM, Timmins PF 3rd, Alvarez RD, Rathbun J, Lipinski E, White S, Siverio-Minardi D, Ko E (2020). Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. Gynecologic oncology, 156(3), 701-709.
- Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo M (2020). High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecologic oncology, 156(2), 349-356.
- Kuznicki M, Mallen A, McClung EC, Robertson SE, Todd S, Boulware D, Martin S, Quilitz R, Vargas RJ, Apte S (2020). Dual antibiotic prevention bundle is associated with decreased surgical site infections. International journal of gynecological cancer, 30(9), 1411-1417.
- Hoffman MS, Xiong Y, Apte S, Roberts W, Wenham R (2019). Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice. Gynecologic oncology, 155(2), 359-364.
- Bulls HW, Hoogland AI, Kennedy B, James BW, Arboleda BL, Apte S, Chon HS, Small BJ, Gonzalez BD, Jim HS (2019). A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecologic oncology, 152(2), 310-315.
- Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS (2018). Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Am J Obstet Gynecol, 218(4), 436.e1-436.e7.
- Apte S (2017). An oncologist's perspective: preparation for new payment models in cancer care. The American journal of managed care, 23(5 Spec No.), SP169-SP172.
- Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham R (2017). Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC cancer, 17(1), 407.
- Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster J (2016). Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecologic oncology, 140(2), 259-63.
- Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad M (2016). Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. International journal of gynecological cancer, 26(3), 553-60.
- Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet (2016). Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. Oncology letters, 11(1), 323-329.
- Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster J (2016). Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Molecular and clinical oncology, 4(3), 399-404.
- Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster J (2015). BAD-mediated apoptotic pathway is associated with human cancer development. International journal of molecular medicine, 35(4), 1081-7.
- Bush SH, Apte S (2015). Robotic-Assisted Surgery in Gynecological Oncology. Cancer control, 22(3), 307-13.
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR 3rd, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone J (2015). Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network, 13(4), 395-404.
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL, National Comprehensive Cancer Network (2015). Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 13(11), 1321-31.
- Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte S (2015). Metastatic VIPoma presenting as an ovarian mass. International journal of surgery case reports, 17, 167-9.
- Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster J (2014). Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncology reports, 31(1), 376-83.
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR 3rd, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes (2014). Uterine neoplasms, version 1.2014. Journal of the National Comprehensive Cancer Network, 12(2), 248-80.
- Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM (2013). Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol, 208(6), 501.e1-7.
- Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM (2013). Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol, 209(6), 576.e1-576.e16.
- Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord A (2013). A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecologic oncology, 130(1), 19-24.
- Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster J (2013). Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecologic oncology, 131(1), 207-12.
- Phillips KM, Faul LA, Small BJ, Jacobsen PB, Apte SM, Jim H (2013). Comparing the retrospective reports of fatigue using the Fatigue Symptom Index with daily diary ratings in women receiving chemotherapy for gynecologic cancer. Journal of pain and symptom management, 46(2), 282-8.
- Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster J (2013). A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncology reports, 29(5), 2011-8.
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M, National Comprehensive Cancer Network (2013). Cervical cancer. Journal of the National Comprehensive Cancer Network, 11(3), 320-43.
- Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM (2012). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer, 106(12), 1967-75.
- Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster J (2012). The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecologic oncology, 124(1), 119-24.
- Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster J (2012). The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. International journal of oncology, 41(1), 179-88.
- Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster J (2012). Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. International journal of gynecological cancer, 22(6), 960-7.
- Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster J (2012). BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Journal of gynecologic oncology, 23(1), 35-42.
- Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster J (2011). BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clinical cancer research, 17(19), 6356-66.
- Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen P (2011). Fatigue, depression, sleep, and activity during chemotherapy: daily and intraday variation and relationships among symptom changes. Annals of behavioral medicine, 42(3), 321-33.
- Ramirez I, Chon HS, Apte S (2011). The role of surgery in the management of epithelial ovarian cancer. Cancer control, 18(1), 22-30.
- Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM (2010). Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol, 203(2), 158.e1-40.
- Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR 3rd, Martin L, Morgan MA, Morgan RJ Jr, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Valea FA, National Comprehensive Cancer Networks (2010). Cervical cancer. Journal of the National Comprehensive Cancer Network, 8(12), 1388-416.
- Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS (2009). Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol, 201(1), 116.e1-3.
- Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman R (2009). A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecologic oncology, 113(2), 210-5.
- Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster J (2009). MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecologic oncology, 113(2), 249-55.
- Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham R (2009). Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. Journal of surgical oncology, 100(6), 511-4.
- Humphrey MM, Apte S (2009). The use of minimally invasive surgery for endometrial cancer. Cancer control, 16(1), 30-7.
- Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster J (2009). Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. International journal of gynecological cancer, 19(9), 1564-9.
- Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster J (2008). MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecologic oncology, 110(2), 206-15.
- Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman R (2006). Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. Journal of translational medicine, 4, 16.
- Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler I (2004). Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic oncology, 93(1), 78-86.
- Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler I (2002). Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clinical cancer research, 8(7), 2413-22.
- Vaccarello L, Apte SM, Copeland LJ, Boutselis JG, Rubin S (1999). Endometrial carcinoma associated with pregnancy: A report of three cases and review of the literature. Gynecologic oncology, 74(1), 118-22.
- Bumgardner GL, Li J, Apte S, Heininger M, Frankel W (1998). Effect of tumor necrosis factor alpha and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice. Hepatology (Baltimore, Md.), 28(2), 466-74.
- Vaccarello L, Apte SM, Diaz PT, Lewandowski GS, Copeland L (1997). Respiratory failure from metastatic choriocarcinoma: a survivor of mechanical ventilation. Gynecologic oncology, 67(1), 111-4.
- Hammer DA, Tempelman LA, Apte SM (1993). Statistics of cell adhesion under hydrodynamic flow: simulation and experiment. Blood Cells, 19(2), 261-75; discussion 275-7.
- Hammer DA, Apte SM (1992). Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. Biophys J, 63(1), 35-57.
Case Report
- Wells AE, Mallen AM, Bui MM, Reed DR, Apte S (2019). NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report. Gynecologic oncology reports, 28, 141-144.
News & Podcasts
Huntsman Cancer Institute News
- Letter of Hope from Sachin Apte, MD, MS, MBA, Gynecologic Oncologist
- Highlights of Huntsman Cancer Institute Awards and Appointments Spring 2026
- Portneuf Cancer Center and Huntsman Cancer Institute Announce Affiliation to Serve Patients in Southeast Idaho
- Discovery Innovations Special Edition 2026
- Why Are Young People Getting Cancer?
- Talks with Docs: Sachin Apte, MD
- Reflections on my First Year
- How COVID Vaccinations Can Help Cancer Patients
- Huntsman Cancer Institute Statement on Colorectal Cancer Screening
- Sachin Apte Joins as Chief Clinical Officer
Dr Apte has been a blessing in my cancer journey. I felt that we connected from the first visit. He has a way of explaining things so I am assured I have a complete understanding of what needs to be done with my care. I never feel like decisions are being made without my input. Dr Apte's calm assurance soothes my anxiety each time I meet with him.
Excellent doctor. He explains things well and has a caring and understanding bedside manner.
Dr. Apte is the best! He made sure I understood all the parameters of my diagnosis and care. His knowledge is great but not in an arrogant way. He always made sure I had a clear understanding of all aspects of my care.
Dr Apte was the best. I felt valued and validated in every way. He was concerned about my comfort during the exam. He made sure that things were explained throughly in a way I could totally understand. Though surgery is in my near future, I have no doubt that will be carried out with the utmost care and diligence. I'm grateful to have Dr Apte at the helm with my care.
Just excellent. I pray none of my friends or family need his services, but if they do, he's the best.
DR Apte is wonderful. So kind and really cares about you.
DR Apte is very respectful and positive. He does not rush you through through your visit and listen to your concerns.
I am very pleased with the outcome of my surgery that Dr. Apte performed. He made a concerning health issue easy to understand so that I could make an informed decision. He and his staff are kind and caring allowing me to feel welcome and as comfortable as possible. I am happy to recommend him.
Courteous, kind, and just the best!
He so Caring and listens to you. I'm so glad he's Doctor
Very intense knowledge and extremely professional. Both he and his staff are friendly and great communicators.
Very professional
He is so caring and really talks to you and explains everything so you understand it.
Dr. Apte is very easy to talk to and very respectful to me as well as my husband and daughter who were with me. I have every confidentance in his knowledge and concern with my ongoing care plan.
I will recommend Dr Sachin he is a great doctor
Very understandable, patient and easy to talk to.
He was so very professional and caring.
He is a wonderful, caring Doctor who make me feel safe.
Dr Apte is very personable and addresses my concerns
Very great Doctor
He is very respectful and friendly. He listens and explains well. Most important, he does not rush you through the appointment. Very happy he is my doctor!